Newsroom · Sioux Falls

Medicare Coverage for COPD in Sioux Falls 2026: Pulmonary Rehab, Home Oxygen, Inhaler Costs, and the $2,100 Part D Cap

With 5.6% of Minnehaha County adults living with COPD, understanding what Medicare actually pays — and what it leaves open — is the difference between a manageable condition and a financial burden.

Big Sioux Benefits Data Desk

Published July 23, 2026 · 10 min read · Sourced from CMS.gov & CDC PLACES

Chronic obstructive pulmonary disease (COPD) is the 7th most prevalent tracked condition among Minnehaha County adults — yet it generates some of the most frequent and expensive Medicare claims of any chronic condition. Pulmonologist visits, pulmonary rehabilitation sessions, home oxygen equipment, nebulizers, and a stack of daily inhalers can quickly turn a "managed condition" into a series of 20%-of-approved-amount bills that add up with no annual ceiling under Original Medicare.

This guide maps every Medicare benefit relevant to COPD management in 2026 — what each part covers, what you pay, how the five local Medicare Advantage PPOs compare, and how the landmark $$2,100 Part D cap changes the math for Sioux Falls beneficiaries on high-cost COPD medications. Every figure comes from federal data: the CMS PY2026 plan landscape, CMS county enrollment, CMS star ratings, CMS Hospital Compare, and CDC PLACES local health data.

What COPD costs under Original Medicare: the 20% gap with no ceiling

Original Medicare's cost-sharing structure for outpatient care is consistent across every service COPD generates. You pay the $$283 Part B annual deductible once per calendar year, then $20% of every Medicare-approved amount for the rest of the year — for pulmonologist visits, pulmonary function tests, pulmonary rehabilitation sessions, home oxygen rentals, and nebulizer equipment. There is no annual ceiling on that 20% under Original Medicare.

For a COPD patient with multiple quarterly pulmonologist visits, an active pulmonary rehabilitation course, and home oxygen equipment, that 20% exposure can accumulate to several thousand dollars in a given year. Here is the full coverage map:

Sources: CMS Medicare Monthly Enrollment by County (2026); CMS 2025 Part A & B cost-sharing fact sheet; CMS PY2026 Part D cost rails.

Two items deserve special attention. First, inhalers you self-administer (the metered-dose and dry-powder inhalers your pulmonologist prescribes) are Part D, not Part B — your formulary tier decides what you pay, not the Part B coinsurance table. Second, if you use a nebulizer (a DME machine Medicare covers at 80/20), the drug administered through it may qualify under Part B rather than Part D, but specific medical documentation criteria apply.

Part B pulmonary rehabilitation: what Sioux Falls COPD patients actually get

Pulmonary rehabilitation is one of Medicare's most evidence-supported COPD benefits — and one of the least-used. A CMS-approved PR program provides supervised exercise training, disease-management education, and psychosocial counseling, all shown to reduce hospitalizations and improve quality of life for COPD patients. Medicare Part B covers PR sessions at 80%, leaving you with the 20% coinsurance after the annual Part B deductible.

To qualify, your physician must certify that you have moderate-to-severe COPD (per the clinical criteria established by CMS). The benefit covers up to 36 sessions per benefit period — typically delivered two to three times per week across 12 to 18 weeks — with additional sessions available if your physician documents continued medical necessity. Sessions must occur in a CMS-approved hospital outpatient setting or physician office facility.

In Sioux Falls, both Sanford and Avera operate pulmonary rehabilitation programs. Your plan's network alignment to the health system where your pulmonologist practices directly affects whether you access PR at the lower in-network rate. Confirming in-network status before your referral saves cost and paperwork.

Home oxygen and nebulizers: COPD equipment under Part B DME

Medicare Part B covers home oxygen equipment and nebulizers as durable medical equipment (DME) when medically necessary. The 80/20 cost-sharing applies: Medicare pays 80% of the approved amount; you pay 20% after the Part B deductible. There is no annual limit on that 20% under Original Medicare.

For home oxygen specifically, your physician must document that your blood oxygen saturation level meets Medicare's clinical threshold (generally at or below 88% at rest or with activity, confirmed by blood gas measurement or oximetry). Medicare rents the equipment from a Medicare-certified DME supplier rather than purchasing it outright; you pay 20% of the approved monthly rental rate for as long as Medicare covers it.

For nebulizers, Medicare covers the machine as DME and — under specific criteria — the inhaled drug used in it may qualify as a Part B supply. The criteria are strict: the drug must be medically necessary, FDA-approved for nebulizer administration, and administered via the DME device rather than a standard handheld inhaler. Standard rescue and maintenance inhalers prescribed for self-administration are always Part D.

Part D and your COPD inhalers: tier math and the $2,100 cap

For most COPD patients, prescription drug spending is where the real cost variation lives. The formulary tier of your specific inhalers — not the plan's headline premium — determines how much you actually pay at the pharmacy. Here is how the tier system typically maps to COPD drugs:

Generic rescue inhalers (such as generic albuterol MDIs) generally land on Tier 1 or Tier 2, meaning low copays and often no deductible. Brand-name maintenance inhalers — including long-acting beta agonist and muscarinic antagonist combinations (LABA/LAMA) — typically land on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), where the drug deductible applies and cost-sharing runs higher. Specialty biologics approved for severe COPD fall on Tier 5, where coinsurance is typically 25% of the drug's cost after the deductible.

Source: CDC PLACES: Local Data for Better Health, County 2023 (2023), adult prevalence, Minnehaha County.

The 2026 Part D out-of-pocket maximum of $2,100 is the most significant drug-cost change in Medicare history for COPD patients on expensive medications. Before 2025, Part D spending had no ceiling — a patient on a Tier 5 specialty biologic could face drug costs of $10,000 or more in a year. Starting in 2026, once your cumulative out-of-pocket drug spending reaches $$2,100 in a calendar year, you pay $0 for any covered drug for the rest of that year.

The standard Part D drug deductible is capped at $$615 in 2026. Different plans set their deductible below this ceiling. Across the five Sioux Falls Medicare Advantage PPOs, drug deductibles range from $300 to $615 — a meaningful difference when you are filling maintenance inhalers every month.

The 5 Sioux Falls Medicare Advantage PPOs for COPD patients

For COPD patients in Minnehaha County, all five standard Medicare Advantage PPOs carry a 3.5-star CMS rating for 2026 — the same across the board. The meaningful differences for COPD management come down to three things: the drug deductible (which hits maintenance inhaler costs every January), the plan's network alignment with your pulmonologist, and the plan's annual out-of-pocket maximum, which caps what you can owe in a high-utilization year.

Source: CMS Medicare Advantage / Part D Landscape (PY2026) & CMS Medicare Advantage & Part D Star Ratings (2026), Minnehaha County 2026.

For COPD patients whose primary focus is drug cost, the drug deductible is the first filter: Align ChoicePlus ($0 premium, $350 deductible) and Align ChoiceElite ($66/month, $300 deductible) carry the lowest drug deductibles in the market, which matters when you're refilling maintenance inhalers 12 times a year. Aetna Signature and Aetna Enhanced Extra carry the $615 ceiling deductible. All five plans cover the $2,100 annual Part D OOP cap — the cap is a federal requirement, not a plan feature.

Beyond the drug deductible, confirm your specific inhalers on each plan's formulary before you enroll. Tier placement can vary across carriers for the same brand-name medication, and a Tier 4 vs. Tier 3 placement for a brand LABA/LAMA combination can mean hundreds of dollars of difference per year even within the same deductible structure.

Medigap Plan G vs. Plan N for COPD patients

If you choose Original Medicare plus a Medigap supplement instead of Medicare Advantage, two plans dominate for Medicare beneficiaries who first became eligible after January 1, 2020: Plan G and Plan N. Both close the most significant gaps COPD creates under Original Medicare.

Source: CMS Publication 02110 — Choosing a Medigap Policy (standardized plans per 42 CFR §403.205).

For COPD patients with frequent pulmonologist visits, Plan G's $0 office copay is a meaningful advantage over Plan N's $20 per visit. If you see your pulmonologist quarterly and attend two rounds of pulmonary rehab over the year, those $20 copays add up. The break-even point between Plan G's higher premium and Plan N's copays depends on your visit frequency — discuss your utilization pattern with a licensed agent when comparing.

Both plans work with any provider that accepts Medicare — including both Sanford USD Medical Center and Avera McKennan in Sioux Falls — giving COPD patients the provider flexibility that Medicare Advantage network plans cannot always match.

Sanford vs. Avera: the pulmonology network question in Sioux Falls

In Sioux Falls, the hospital network question is never purely academic. It directly determines which specialist you see at in-network rates. Both major health systems in Sioux Falls hold strong CMS star ratings:

Source: CMS Hospital Compare — Overall Star Ratings.

Sanford Health operates the Align ChoicePlus and Align ChoiceElite Medicare Advantage PPO plans through its affiliated insurer — which means those plans naturally anchor to the Sanford network. If your pulmonologist, respiratory therapist, and pulmonary rehabilitation program are all within the Sanford system, one of the Align plans may align your care and your coverage more cleanly. If your care team is primarily at Avera, the Aetna or Wellmark PPOs may serve you better.

All five plans are PPOs — they do cover out-of-network providers, but at a higher cost-sharing rate. For COPD patients who need consistent, ongoing specialist access, staying in-network for routine pulmonology visits and PR sessions is the practical way to control costs throughout the year. Confirm your specific pulmonologist's in-network status for 2026 before you commit to a plan during AEP (October 15 through December 7).

Vaccines Medicare covers at $0 for COPD patients

Respiratory infections are a leading driver of COPD exacerbations and hospitalizations. Medicare Part B covers several vaccines at $0 cost-sharing — no deductible, no copay — that are particularly important for COPD patients:

• Pneumococcal vaccines (PPSV23 and PCV15 or PCV20): Medicare covers both pneumococcal vaccines at $0. COPD patients are at elevated risk for pneumococcal pneumonia — both vaccines are recommended by the CDC Advisory Committee on Immunization Practices for adults 65 and older.
• Annual influenza (flu) vaccine: Covered at $0 each flu season. Flu exacerbations are one of the most common COPD hospital admission triggers.
• COVID-19 vaccines and boosters: Covered at $0 under Part B when administered by a Medicare-enrolled provider.
• RSV vaccine: Covered at $0 for adults 60 and older. RSV is a significant respiratory virus risk for COPD patients.

All five Sioux Falls Medicare Advantage PPOs cover these vaccines at the same $0 rate under the Part B benefit — there is no cost advantage to choosing one plan over another on vaccines alone. The real preventive step is simply making sure your care team knows you are on Medicare and administers the vaccines through a Medicare-enrolled provider.

What to watch for COPD coverage in 2027

1. Annual Notice of Change (ANOC) in September 2026: If you are on a Medicare Advantage plan, your plan must mail you an ANOC by September 30, 2026 showing any premium, deductible, or formulary changes for 2027. Review it specifically for your inhalers — brand formulary tier changes are one of the most frequent triggers for plan-switching at AEP.
2. Part D $2,100 cap indexing: The $2,100 ceiling may adjust for 2027 based on CMS rulemaking. Beneficiaries on Tier 5 specialty COPD biologics should monitor CMS announcements for any changes to the cap amount or the calculation method.
3. Pulmonary rehabilitation benefit expansion: CMS has signaled interest in expanding access to PR programs and potentially covering PR for non-COPD respiratory conditions. Check your plan's coverage terms each October for changes.
4. Home oxygen documentation renewal: Medicare requires periodic recertification of home oxygen medical necessity. Watch for your supplier's documentation requests to avoid interruption in coverage — gaps in documentation can pause Medicare's 80% payment.
5. New COPD biologics entering the formulary: The COPD biologic landscape is evolving rapidly. New FDA approvals may move from non-formulary to Tier 5 on your plan's 2027 formulary. The $2,100 OOP cap applies, but checking your plan's 2027 formulary during AEP remains critical.

How we know all this: Big Sioux Benefits runs every article through a data desk that cross-references public federal data — the CMS PY2026 plan landscape, CMS county enrollment, 2026 star ratings, CMS Hospital Compare, CDC PLACES county health data, and CMS-published Part A/B cost-sharing figures — built by Strategic AI Architects. Every number here comes from a public federal dataset. This is education, not advice; confirm your specific plan, costs, formulary placement, and eligibility with a licensed agent or Medicare.gov. We take no payment from any carrier to feature a plan. Not connected with or endorsed by the U.S. government or the federal Medicare program.